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Abstract: Vitamin D3 is known to be liposoluble and its release could be a factor limiting the rate
of absorption. It was presumed that the presence of fat could favor absorption of vitamin D3.
However, as bioavailability is related not only to the active molecules but also to the formulations
and excipients used, the optimization of the pharmaceutical form of vitamin D3 is also important.
The objective of this study was to evaluate if there is a food effect on absorption when a high dose of
vitamin D3 is completely solubilized in an oily solution. In the present cross-over study, 88 subjects
were randomized and received a single dose of 50,000 IU of vitamin D3 in fasting state or with
a standardized high-fat breakfast. Assessment of serum concentrations of 25 hydroxyvitamin D3
(25(OH)D3) was performed three, five, seven, 14, 30 and 60 days after supplementation. In fed
and fast conditions, the 25(OH)D3 serum concentrations were significantly higher than the baseline
value three days after administration and remained significantly higher during the first month. No
significant difference between fasting vs. fed conditions was observed. It is therefore concluded that
the vitamin D3 absorption from an oily solution was not influenced by the presence or absence of
a meal.
Keywords: 25-hydroxyvitamin D3; absorption; high fat; fasting
1. Introduction
The importance of vitamin D in health is well documented in terms of its effect on bone, muscle
strength, fracture and fall risks. Recently there has been a growing body of evidence that vitamin D
may play a role in immune function, cardiovascular health and cancer prevention [1–3]. However,
it has also been recognized that vitamin D insufficiency remains common in children and adults [4].
The essential question of how much vitamin D is needed for optimal bone and global health remains
unresolved. Additionally, the 25-hydroxyvitamin D3 (25(OH)D3) response to supplementation with
vitamin D3 varies widely among individuals. Several factors are known to contribute to this variability
including genetic variants in the vitamin D binding proteins and in the enzyme that hydroxylates
vitamin D in the liver but also the starting serum concentration of 25(OH)D3, the body mass index,
the age and the serum albumin concentration [5,6]. The presence of a meal and the fat content of that
meal may also be important. Because vitamin D is poorly soluble in water, it is hypothesized that
absorption would be improved if patients were instructed to take their vitamin D supplement with a
meal [7–11]. Concerning vitamin D bioavailability in supplements, the effect of the vehicle substance
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used was recently reviewed. When the information was combined, oil-soluble vehicles produced the
greatest rate of change in mean serum 25(OH)D per 100,000 IU. However, there were discrepancies
among the studies which identify important areas for future research [12].
In this new randomized, open, cross-over study, the objective was to determine whether a single
dose of 50,000 IU of vitamin D3 with food improves the absorption and increases serum concentrations
of 25-hydroxyvitamin D3.
2. Materials and Methods
2.1. Methodoloy
This was an interventional, randomized, open, two-treatment, two-period, cross-over study. The
study was conducted in one site in Belgium. This trial was reviewed and approved by an Independent
Ethics Committee and by the Belgian Competent Authorities (EudraCT No. 2014-003779-48).
This study was performed in accordance with the ethical principles that have their origin in the
Declaration of Helsinki and that are consistent with Good Clinical Practice (GCPs/ICH E6-Step 5)
and the requirements according to the National Drug Law in effect in Belgium in which the study
was performed.
The study began in the fourth week of October 2014 and ended in March 2015, a period of the
year during which cutaneous synthesis of vitamin D from UV-B sunlight was negligible in Belgium.
88 subjects were included and randomized into two groups of 44 subjects. A screening visit was
performed to check the eligibility of each subject in the study. Subjects meeting all the inclusion and
none of the exclusion criteria were randomized in one of the two sequences of treatment. The study
extended over two periods of 60 ˘ 3 days. During each period the subject returned to the site for blood
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The nutrient composition of the breakfast given is shown in Table 1. Breakfast included two fried
or scrambled eggs, two strips turkey, two slices of toast with two pats of butter, 100 g fried potato and
one cup of tea or coffee.
Table 1. Composition of the breakfast.
Composition High-Fat Breakfast
Total fat 52.7 g
Saturated fatty acid (SFA) 11.4 g
Polyunsaturated fatty acid (PUFA) 12.35 g
Monosaturated fatty acid (MUFA) 24.25 g
Total carbohydrates 48.72 g
Total protein 28.95 g
Total calories 782 kcal
Vitamin D3 was taken at the study site. The investigator or designee checked that the subjects
took the treatment correctly. This was ensured by checking that the ampoules were empty after intake.
The subjects stayed at the study site during the 4 h after the vitamin D3 administration and returned
to the site for the second intake (50,000 IU) 60 ˘ 3 days after. Both vitamin D3 intakes were therefore
separated by a wash-out period of 60 days.
2.2. Study Population
Caucasian (defined as European and North African), male and female healthy volunteers aged
from 18 to 55 years inclusive, with a 25(OH)D3 concentration ě10 ng/mL and ď20 ng/mL and a BMI
between 18 and 25 kg/m2 inclusive were selected. They all gave their written, informed consent to
participate in this trial.
The main exclusion criteria were any unstable clinically significant immunological, neoplastic,
endocrine, hematological, hepatic, cardiac, renal, gastrointestinal, neurological or psychiatric
abnormalities or medical disease; past or current granulomatosis, sarcoïdosis, urinary lithiasis, renal
insufficiency, osteomalacia; abnormal digestive functions and abnormal thyroid function. Subjects
who had a serum creatinine >150 µmol/L and an albumin corrected serum calcium >2.65 mmol/L
were excluded at screening. Finally, subjects who used a UV light solarium or any type of vitamin
D supplement within two months before the screening visit or planned to travel outside European
countries during the study were excluded. Subjects were not allowed to take concomitant medications
that were expected to interfere with the interpretation of study data.
2.3. Laboratory Assessment
The following tests were performed at the screening visit: RBC, platelets, hematocrit, hemoglobin,
WBC and differential count, sodium, potassium, urea, albumin, SGPT/ALAT, SGOT/ASAT, ALP,
GGT, total bilirubin, creatinine, calcium, phosphate, TSH and blood β-HCG pregnancy test. A prick
finger blood test for a glucose level was performed to confirm the fasting status at each period. All the
analyses were performed at the ISO 151198 clinical chemistry laboratory of the University of Liège
(Belgium). The LC MS/MS VDSP traceable method was used for serum 25(OH)D measurement as
described previously [13]. The samples were measured with the MassChrom® 25-OH-Vitamin D3/D2
LC MS/MS kit (Chromsystems, Gräfelfing, Germany) including 3-epi-25-OH-Vitamin D3 upgrade
on the AB SCIEX QTRAP® 5500 system (AB Sciex, Framingham, MA, USA). This method is able to
measure the serum 25(OH)D2 and 25(OH)D3 separately from their epimeric forms 3-epi-25(OH)D.
In the following analysis, only the serum 25(OH)D3 concentration was considered as the 25(OH)D2
concentration was <1 ng/mL in each sample.
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2.4. Statistical Methods
The statistical tests were one-tailed and the significance threshold retained was 2.5%. The
one-sided 97.5% confidence interval of the difference between the means in the two groups was
calculated. The statistical analysis was performed using SAS/STAT software version 9.4. (SAS Institute
Inc., Cary, NC, USA) of the SAS system for Windows. Baseline value was the serum 25(OH)D3 level
measured at predose on the first day of each period. The serum concentrations of 25(OH)D3 at each
time point were compared by a mixed model. Fixed factors were the administration of food, period,
sequence and random factors were baseline (day 1 predose), BMI and subject ˆ sequence interaction.
Change from baseline to day 3, 5, 7, 14, 30 and 60 of each period was calculated by subtracting the
baseline value (day 1 predose) from the value at each time point.
3. Results
All randomized subjects (88) completed the two phases of this cross-over study.
The main analysis was conducted on the ITT analysis set. Results were confirmed in two
robustness analyses differing by the imputation methods of missing data and in the per protocol subset.
The main demographic characteristics of the subjects are presented in Table 2. As Vitamin D3 was
taken under the supervision of the study personnel, compliance was 100%.
Table 2. Demographic data of the 88 subjects included in the study.
Variables All Subjects (n = 88)
Male, n (%) 37 (42)
Female, n (%) 51 (58)
Age, year, Mean ˘ SD 31.3 ˘ 8.8
min-max; median 19.0–55.0; 28.0
BMI, kg/m2, Mean ˘ SD 22.3 ˘ 2.0
min-max; median 18.2–25.0; 22.2
25(OH)D3, ng/mL, Mean ˘ SD 16.5 ˘ 2.3
min-max; median 11.0–20.0; 17.0
Evaluation of 25(OH)D3
After a single administration of 50,000 IU/mL of vitamin D3 under fasting conditions or with
a high-fat meal, the serum concentration of 25(OH)D3 rapidly increased after three days (25.1 ˘ 4.3
vs. 25.1 ˘ 4.9 ng/mL), reached a plateau from day 3 to day 14 (25.6 ˘ 4.3 vs. 25.7 ˘ 4.6 ng/mL) and
decreased until day 60 (Table 3). After 60 days, the 25(OH)D3 serum level was close to the baseline
value measured before vitamin D3 administration (17.2 ˘ 3.6 vs. 17.8 ˘ 4.0 ng/mL). The increment
was similar when the single dose of vitamin D3 was taken with a high-fat meal or in fasting conditions.
There were no significant group differences in 25(OH)D3 concentrations at either three, five, seven, 14
or 30 days (p > 0.059) after a single administration of 50,000 IU/mL of vitamin D3.
Table 3. Serum 25(OH)D3 concentrations (ng/mL) following a single dose of vitamin
D3 supplementation.
Blood Sampling Day
Fasting (n = 88) High Fat (n = 88)
Mean˘ SD Min–Max Mean˘ SD Min–Max
Baseline (day 1) 17.1˘ 4.0 9.0–26.0 16.6˘ 4.2 6.0–26.0
Day 3 25.1˘ 4.3 18.0–37.0 25.1˘ 4.9 14.0–40.0
Day 5 24.7˘ 4.0 15.0–35.0 24.8˘ 4.2 15.0–35.0
Day 7 25.5˘ 4.1 17.0–39.0 24.9˘ 4.5 16.0–37.0
Day 14 25.6˘ 4.3 18.0–39.0 25.7˘ 4.6 16.0–37.0
Day 30 23.6˘ 4.8 15.0–44.0 23.7˘ 4.5 14.0–35.0
Day 30 17.2˘3.6 11.0–26.0 17.8˘ 4.0 10.0–30.0
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Similarly, no effect of fasting versus fed conditions was observed for the Area Under the
Curve calculated after 30 days (AUCD1–D30) and 60 days (AUCD1–D60) (Figure 2). The estimated
difference between means was not significant (p > 0.039). AUCD1–D30 was 222.2 ˘ 93.3 ng ˆ 24 h/mL
in the fasting period and 236.4 ˘ 93.6 ng ˆ 24 h/mL in the high-fat period and AUCD1–D60 was









Figure  2.  Evaluation  of  serum  25(OH)D3  concentrations  following  a  single  dose  of  vitamin  D3 
supplementation. Solid line: Fasting conditions; Dashed line: High fat conditions. 
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healthy men and women concluded  that diets  rich  in monounsaturated  fatty acids  (MUFA) may 
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4. Discussion
In the present study, e found no difference bet een the increase in 25( ) 3 seru
concentrations hen vitamin D3 was taken from an oily supplement in the presence or absence
of a meal. The study was well designed; all subjects received their vitamin D3 supple ent under both
conditions (fasting and with a high-fat meal); the meal contained 52.77 g of fat with a high MUFA:PUFA
ratio (1.96); the 25(OH)D3 level was not significantly different at baseline; and the obtained mean
increase in 25(OH)D3 and its variability were as observed in other studies performed with the same
vitamin D3 supplement, which confirms the reliable and reproducible absorption [14,15].
Interestingly, recent studies found different results from ours and suggested that taking a vitamin
D supplement with the largest meal of the day improved vitamin D absorption. In a randomized,
placebo-controlled study including 64 subjects, Raimundo et al. concluded that a single oral dose of a
powder capsule of 50,000 IU vitamin D3 given with food increased the 25(OH)D3 serum concentrations
after two weeks [8]. They observed that the mean increase was larger when the meal contained at least
15 g of fat. Another study conducted by Niramitmahapanya et al. in 152 healthy men and women
concluded that diets rich in monounsaturated fatty acids (MUFA) may i prove the effectiveness of
powder tablets of vita in D3 supplements while those rich in polyunsaturated fatty acids (PUFA) ay
decrease the response [10]. A single-dose study conducted by Dawson-Hughes et al. in 50 subjects after
supplementation with 50,000 IU powder tablets of vitamin D3 compared the influence of three different
fat-containing meals [11]. The author also concluded that the presence of fat in a meal significantly
enhances absorption of vitamin D3, but the MUFA:PUFA ratio of the fat in that meal does not influence
its absorption.
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It is interesting to note that in these studies showing a food effect on vitamin D absorption,
the matrix of the supplement was powder contrary to the present study where the vitamin D3 was
solubilized in an oily solution [7,8,10,11]. A systematic review performed recently by Grossmann et al.
confirmed that vitamin D in an oil vehicle produced a greater 25(OH)D response than vitamin D in a
powder or in an ethanol vehicle [12]. Vitamin D3 is known to be liposoluble and its release could be a
factor limiting the rate of absorption. It was presumed that the presence of fat could favor absorption
of vitamin D3. However, as bioavailability is related not only to the active molecules but also to the
formulations and excipients used, the optimization of the pharmaceutical form of vitamin D3 is also
important. In the present study, the hypothesis was that the solubilization of vitamin D3 in oil could
help to guarantee that patients reach the expected bioavailability independently of the concomitant
intake of food.
5. Conclusions
In the present study, we can conclude that the bioavailability of a high single dose of vitamin D3
(50,000 IU) administered as an oral oily solution was not influenced by the presence or absence of
a meal.
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